TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00613145

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine and Sorafenib
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine and Sorafenib
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Study: NCT02045563

Intervention type: OTHER
Intervention: prise de sang

Intervention type: OTHER
Intervention: prise de sang

Intervention type: OTHER
Intervention: prise de sang

Intervention type: OTHER
Intervention: magnetic resonance imaging and magnetic resonance spectroscopy

Intervention type: OTHER
Intervention: magnetic resonance imaging and magnetic resonance spectroscopy

Intervention type: OTHER
Intervention: magnetic resonance imaging and magnetic resonance spectroscopy
Study: NCT04395586

Intervention type: OTHER
Intervention: Culture
Description: Culture
Study: NCT03871907

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital technology
Description: Lifestyle-Focused Text Messaging
Study: NCT03614845

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VCV
Description: after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCV-VG
Description: after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasonography
Description: all patients will be performed lung ultrasonography pre and postoperatively

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasonography
Description: all patients will be performed lung ultrasonography pre and postoperatively
Study: NCT03161405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole solution
Study: NCT03697798

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix®-IPV combination vaccine
Description: A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix®-IPV combination vaccine
Description: A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix®-IPV combination vaccine
Description: A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix®-IPV combination vaccine
Description: A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
Study: NCT02631772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir x 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
Study: NCT03914183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mCPN Intervention
Description: Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened

Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Use of standard of care insulin pen needle
Study: NCT04027205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise
Description: A programme of physiotherapist-led exercise over approximately 12 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair
Description: Surgical repair of the rotator cuff plus usual post-operative rehabilitation
Study: NCT00626184

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 dose levels of ALV003
Description: 4 dose levels of ALV003 vs placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 dose levels of ALV003
Description: 4 dose levels of ALV003 vs placebo
Study: NCT02386618

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardized endoscopic treatment of local residual neoplasia
Description: Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN \> 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN \> 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
Study: NCT01504763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chair massage
Description: Chair massage for 15 minutes once a week for 10 weeks.
Study: NCT03024515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioids titration
Description: Standard Practice Arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: predefined titration steps
Description: comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
Study: NCT03951363

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interactive Obesity Treatment Approach (iOTA)
Description: The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
Study: NCT01691456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast Sodium Oral Granules 4mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Description: Montelukast Sodium Oral Granules 4mg
Study: NCT04737486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-001
Description: AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-001
Description: AV-001 (mpaBr) Cl for Injection 2.5 mg/mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D-PBS

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D-PBS
Study: NCT00264394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Updated CHD risk profiles
Description: Provision of computer generated CHD risk profiles

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines
Description: provision of guidelines for CHD risk factor management only
Study: NCT01922921

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER-2/neu Intracellular Domain Protein
Description: Given ID

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu Intracellular Domain Protein
Description: Given ID
Study: NCT01581658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI10773 medium dose tablet single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI10773 medium dose tablet single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI10773 medium dose tablet single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI10773 medium dose tablet single dose
Study: NCT01922921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01577381

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN6G
Description: Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous, 11 doses, 30 minute infusion
Study: NCT02096991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Can 1
Description: drink the beverage in a can and a glass bottle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Can 1
Description: drink the beverage in a can and a glass bottle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Can 1
Description: drink the beverage in a can and a glass bottle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Can 2
Description: Consume two canned beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Can 2
Description: Consume two canned beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Can 2
Description: Consume two canned beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass
Description: consume two glass bottled beverage

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass
Description: consume two glass bottled beverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass
Description: consume two glass bottled beverage
Study: NCT01074203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery \>12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given.
Study: NCT03981445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARTAS Adapted Patient Navigation
Description: Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
Study: NCT01922921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given per standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given per standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide-K
Description: Given PO

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given per standard of care

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given per standard of care
Study: NCT01914679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RINCE
Description: The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
Study: NCT00459030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention via internet
Description: additional cancer screening information via password protected internet site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention mailed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No additional educational intervention
Study: NCT02354833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Study: NCT01548261

Intervention type: PROCEDURE
Intervention: Donating oral mucosal cells
Description: Donating oral mucosal cells
Study: NCT04255511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Block
Description: Functional appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic appliance
Description: Braces
Study: NCT00282243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus modified release (MR)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study: NCT00496366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
Study: NCT02670876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anti-bullying intervention
Description: The title of each session were as follows :~1. Introduction of intervention and setting rules, building rapport~2. Understanding school bullying (The definition of school bullying and proper coping strategies)~3. Empathy of others ( Practice of understanding victims of school bullying)~4. Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)~5. Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)~6. Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)~7. Communication skills enhancement~8. Increasing self esteem
Study: NCT03136939

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00576771

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV
Description: Pressure Support Ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Neurally Adjusted Ventilatory Assist

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: patient-controlled
Description: assisted controlled MV through a button
Study: NCT01468649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR Imaging with FLARE and Mini-FLARE Imaging System
Description: A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
Study: NCT02811744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-acetate
Description: Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.

Intervention type: DRUG
Group type: OTHER
Intervention: 11C-acetate
Description: Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
Study: NCT04610099

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Banded Sleeve Gastrectomy
Description: banded sleeve gastrectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard SG
Description: Standard SG
Study: NCT03751293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR088
Description: Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg
Study: NCT03642184

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: Dosage adjustment based on glucose targets . Once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Dosage adjustment based on glucose targets. Once daily
Study: NCT01975103

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Topcon Endpoint Management

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Topcon Endpoint Management
Study: NCT02669693

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: bread without olives

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: bread with olives
Study: NCT00492219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard M fixed-bearing or Oxford mobile-bearing prostheses
Description: Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanguard M fixed-bearing or Oxford mobile-bearing prostheses
Description: Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement
Description: Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
Study: NCT00128687

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: risk reduction
Description: Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: risk reduction
Description: Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (\< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
Study: NCT05723887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-Based Intervention Program
Description: Attachment-Based Intervention Program
Study: NCT02091440

Intervention type: DEVICE
Group type: OTHER
Intervention: Implant of the HW005 Ventricular Assist System.
Description: The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
Study: NCT01771783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI-ARB-RI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI-ARB-RI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEI-ARB-RI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB-RI-ACEI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB-RI-ACEI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARB-RI-ACEI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RI-ACEI-ARB
Study: NCT03981445

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: Counseling for PrEP initiation and adherence and, if necessary, HCV treatment will be provided by the clinical counseling staff of the on-site integrated care arm. Adherence counseling will include, but not be limited to, the indications, advantages, and disadvantages (e.g. side effects) of PrEP and HCV treatment in order to help the participant with his/her decision. The counselor will provide any necessary information to the participants and help them to address health and social needs. If required, the counselor will help the patient and physician with insurance-related issues. Adherence counselling will be carried out in a motivational style. The intervention will include five 30-45 minute face-to-face meetings with the participant and the adherence counselor over 6 months.
Study: NCT01804816

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standardized acupuncture administration for 10 sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Intervention
Description: No intervention during this period. This was a control period. Each subject acted as their own control.